Is OPK a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on ModeX pipeline and partnerships, with revenue (ttm) at ~$588 million. The bear case rests on the dominant risk is that OPKO has been unprofitable at the consolidated level (a trailing net loss of about $73 million), so the base business is not yet self-sustaining. Analysts covering it are spread from $3.00 to $8.50, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is that OPKO has been unprofitable at the consolidated level (a trailing net loss of about $73 million), so the base business is not yet self-sustaining. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $3.00, +96.1% from the $1.53 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

ModeX pipeline and partnerships. ModeX Therapeutics is the main source of long-term upside. The most optimistic analyst target on OPK is $8.50, +455.6% from the $1.53 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is that OPKO has been unprofitable at the consolidated level (a trailing net loss of about $73 million), so the base business is not yet self-sustaining. The Labcorp sale adds execution risk: it needs regulatory approvals, the price adjusts with closing revenue, and the $150 million earnout depends on 4Kscore sales that OPKO will no longer control. After the sale, OPKO becomes more dependent on pharma royalties and a pipeline that is highly speculative: ModeX's programs are early-stage, and clinical trials frequently fail, meaning the large partnership milestones may never be earned. Because it is a small-cap with ongoing losses, OPKO may still need to raise capital, which could dilute existing shareholders, and the stock is volatile and sensitive to trial news and sentiment. Pharma revenue depends on a partner (Pfizer) for a key royalty, and litigation and regulatory history around the company and its founder have been a recurring overhang. The most pessimistic published target is $3.00, +96.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (ModeX pipeline and partnerships) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is that OPKO has been unprofitable at the consolidated level (a trailing net loss of about $73 million), so the base business is not yet self-sustaining) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice; Walnut is not an investment adviser. The bull case is that the pending $722 million BioReference sale to Labcorp funds ModeX's antibody pipeline, backed by Merck and Regeneron partnerships worth potentially over $1 billion in milestones. The bear case is that the company loses money, the sale still needs approvals, the pipeline is early-stage and could fail, and it may need to raise capital and dilute shareholders. OPK is speculative and volatile, so weigh it carefully against your portfolio.

OPKO Health is a diversified healthcare company with three parts: a diagnostics business (BioReference Laboratories, including the 4Kscore prostate test), a pharmaceutical business (products like Rayaldee plus a profit share on Pfizer's NGENLA growth-hormone drug), and a clinical-stage biotech, ModeX Therapeutics, developing multispecific antibodies and vaccines. In October 2026 it agreed to sell most of BioReference and the 4Kscore test to Labcorp, after which it plans to focus on its biopharmaceutical business.

ModeX is OPKO's clinical-stage biotech division developing multispecific antibodies and vaccines using its MSTAR technology. Its lead oncology candidate, MDX2001, is a tetraspecific T-cell engager for solid tumors that has advanced through early dosing, with additional immuno-oncology candidates behind it. ModeX has research collaborations with Merck and Regeneron that carry large potential milestone payments if the programs succeed, making it the main long-term value driver for OPK.